Market Cap 18.39M
Revenue (ttm) 26.55M
Net Income (ttm) -91.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -345.46%
Debt to Equity Ratio -1.26
Volume 77,676
Avg Vol 125,932
Day's Range N/A - N/A
Shares Out 28.95M
Stochastic %K 26%
Beta 0.54
Analysts Sell
Price Target $6.00

Company Profile

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and deg...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 768 2170
Address:
170 Park Avenue, Florham Park, United States
NuclearMan
NuclearMan Aug. 4 at 7:35 AM
$CELU The 10Q compliance plan should have been submitted last week but we will not know until Nasdaq give a ruling (anytime in the next two weeks). The plan will basically have been to provide evidence that CELU can fund CFO Squad to complete the financials. That flows back into the loan Barach granted which is in an ambigious state and is hopefully being renegotiated etc. The company is dark because the late financials preclude a lot of stuff they could normally communicate. Everything revolves around the behind-the-scenes financing.
0 · Reply
Nosay
Nosay Aug. 3 at 12:40 PM
$CELU 12 days until q2 are due! What’s the odds we get q1 prior to that? Crazy how quiet. We must have submitted a plan to Nasdaq atleast right?
1 · Reply
NuclearMan
NuclearMan Jul. 31 at 3:09 PM
$CELU An 11% bid-ask spread means a single off-exchange transaction at 26.3k nuked the price. MMs have pulled liquidity until Barach and Bob have sorted the financing.
0 · Reply
NuclearMan
NuclearMan Jul. 30 at 10:32 AM
$CELU Well the 8K on minimum bid delinqency is ticked off. If Hariri and Barach remain quiet on the loan, the market will likely begin pricing in an unresolved senior secured debt risk. Being 'short sale restricted' today helps protect the stock from shorting of the bid. But doesn't protect it from pure selling. If market makers pull liquidity, the wider bid-askrspread could make the price volatile. Worth being prepared for that tbh.
1 · Reply
Coux
Coux Jul. 29 at 9:55 PM
$CELU new 8 K About the price being under 1$
1 · Reply
SkywalkerAR
SkywalkerAR Jul. 29 at 4:22 PM
$CELU bad news on the way?
0 · Reply
NuclearMan
NuclearMan Jul. 29 at 4:22 PM
$CELU Short sale restrictions just kicked in after that 10% drop. The Daily RSI is sub-40. If the company wanted an open goal for a decent PR, this is it.
0 · Reply
NuclearMan
NuclearMan Jul. 29 at 8:51 AM
$CELU This stock really has to declare some kind of resolution to the bridging loan today. I am guessing the dollar delinquency PR will be folded into that 8k. The 10Q did not file so we have to assume CELU submitted a plan to Nasdaq yesterday. Some clarification would be VERY welcome now.
2 · Reply
luckydog2
luckydog2 Jul. 27 at 1:35 PM
$CELU This is good news for Celularity/Biocellgraft. https://www.reddit.com/r/Biocellgraft/s/5c2dqRQ0ka
0 · Reply
Nosay
Nosay Jul. 27 at 12:38 PM
$CELU they haven’t even announced the IMUN thing but other companies they’re obviously working with are. Wonder why the silence. This is kind of big news. Where life bank was limited to a very small set of the population. People having new babies. This is open to all. Could be big if marketed well. Wish I was closer to New Jersey to go and see. And why is it referred to as Celularity campus? Something coming by Wednesday for sure. Barach loan is due.
0 · Reply
Latest News on CELU
Celularity Releases CEO Letter to Shareholders

Jun 3, 2026, 4:15 PM EDT - 2 months ago

Celularity Releases CEO Letter to Shareholders


Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Jun 3, 2026, 8:00 AM EDT - 2 months ago

Celularity Appoints Rick Gonzalez as Chief Commercial Officer


Celularity Receives Nasdaq Notice Regarding Form 10-Q

May 29, 2026, 5:15 PM EDT - 2 months ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q


Celularity Annual report: Q4 2025

Apr 30, 2026, 7:00 AM EDT - 3 months ago

Celularity Annual report: Q4 2025


NEXGEL Appoints Ian Blackman as Chief Financial Officer

Apr 27, 2026, 9:00 AM EDT - 3 months ago

NEXGEL Appoints Ian Blackman as Chief Financial Officer


NexGel closes acquisition of products from Celularity

2026-04-21T15:06:20.000Z - 3 months ago

NexGel closes acquisition of products from Celularity

NXGL


Celularity announces closing of transaction with NexGel

2026-04-21T13:07:46.000Z - 3 months ago

Celularity announces closing of transaction with NexGel


Celularity Announces Closing of Transaction with NexGel

Apr 21, 2026, 8:30 AM EDT - 3 months ago

Celularity Announces Closing of Transaction with NexGel


Celularity secures $35M strategic license deal

2026-03-10T12:41:03.000Z - 5 months ago

Celularity secures $35M strategic license deal


Celularity Registration statement: Registration Filing

Dec 31, 2025, 7:00 AM EST - 7 months ago

Celularity Registration statement: Registration Filing


Celularity Announces Closing of Financing Transactions

Dec 22, 2025, 4:01 PM EST - 8 months ago

Celularity Announces Closing of Financing Transactions


Celularity Registration statement: Registration Filing

Dec 19, 2025, 7:00 AM EST - 8 months ago

Celularity Registration statement: Registration Filing


Celularity announces up to $12M of capital from Philip Barach

2025-12-18T19:15:11.000Z - 8 months ago

Celularity announces up to $12M of capital from Philip Barach


Celularity Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 9 months ago

Celularity Quarterly report: Q3 2025


Celularity Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 9 months ago

Celularity Proxy statement: Proxy Filing


Celularity Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 9 months ago

Celularity Proxy statement: Proxy Filing


Celularity announces publication of Phase 2 study on PDA-002

2025-10-14T12:55:36.000Z - 10 months ago

Celularity announces publication of Phase 2 study on PDA-002


Celularity reports Q1 EPS (84c) vs ($1.03) last year

2025-09-03T12:10:50.000Z - 11 months ago

Celularity reports Q1 EPS (84c) vs ($1.03) last year


Celularity regains compliance with Nasdaq listing rule

2025-09-03T12:10:44.000Z - 11 months ago

Celularity regains compliance with Nasdaq listing rule


Celularity Quarterly report: Q2 2025

Aug 29, 2025, 9:30 AM EDT - 1 year ago

Celularity Quarterly report: Q2 2025


Celularity Quarterly report: Q1 2025

Aug 29, 2025, 12:00 AM EDT - 1 year ago

Celularity Quarterly report: Q1 2025


Celularity receives noncompliance notice from Nasdaq

2025-08-22T21:35:07.000Z - 1 year ago

Celularity receives noncompliance notice from Nasdaq


Celularity Announces Chief Financial Officer Transition

Jun 10, 2025, 4:15 PM EDT - 1 year ago

Celularity Announces Chief Financial Officer Transition


Celularity Earnings release: Q4 2024

May 9, 2025, 4:00 PM EDT - 1 year ago

Celularity Earnings release: Q4 2024


Celularity Annual report: Q4 2024

May 9, 2025, 4:00 PM EDT - 1 year ago

Celularity Annual report: Q4 2024


Celularity Registration statement: Registration Filing

Feb 13, 2025, 7:00 AM EST - 1 year ago

Celularity Registration statement: Registration Filing


Celularity Registration statement: Registration Filing

Jan 30, 2025, 7:00 AM EST - 1 year ago

Celularity Registration statement: Registration Filing


Celularity Quarterly report: Q3 2024

Dec 5, 2024, 6:00 PM EST - 1 year ago

Celularity Quarterly report: Q3 2024


Celularity Inc. Announces Receipt of Nasdaq Notification

Nov 27, 2024, 5:00 PM EST - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notification


Celularity Proxy statement: Proxy Filing

Nov 19, 2024, 7:00 AM EST - 1 year ago

Celularity Proxy statement: Proxy Filing


Celularity Quarterly report: Q2 2024

Nov 6, 2024, 6:00 PM EST - 1 year ago

Celularity Quarterly report: Q2 2024


Celularity Quarterly report: Q1 2024

Oct 16, 2024, 3:30 AM EDT - 1 year ago

Celularity Quarterly report: Q1 2024


Celularity Appoints Richard J. Berman to its Board of Directors

Aug 28, 2024, 4:45 PM EDT - 2 years ago

Celularity Appoints Richard J. Berman to its Board of Directors


Celularity Annual report: Q4 2023

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Celularity Annual report: Q4 2023


Celularity Transcript: Analyst Research & Development Day 2024

May 21, 2024, 12:00 PM EDT - 2 years ago

Celularity Transcript: Analyst Research & Development Day 2024


Celularity Slides: FY 2024

May 21, 2024, 12:00 PM EDT - 2 years ago

Celularity Slides: FY 2024


NuclearMan
NuclearMan Aug. 4 at 7:35 AM
$CELU The 10Q compliance plan should have been submitted last week but we will not know until Nasdaq give a ruling (anytime in the next two weeks). The plan will basically have been to provide evidence that CELU can fund CFO Squad to complete the financials. That flows back into the loan Barach granted which is in an ambigious state and is hopefully being renegotiated etc. The company is dark because the late financials preclude a lot of stuff they could normally communicate. Everything revolves around the behind-the-scenes financing.
0 · Reply
Nosay
Nosay Aug. 3 at 12:40 PM
$CELU 12 days until q2 are due! What’s the odds we get q1 prior to that? Crazy how quiet. We must have submitted a plan to Nasdaq atleast right?
1 · Reply
NuclearMan
NuclearMan Jul. 31 at 3:09 PM
$CELU An 11% bid-ask spread means a single off-exchange transaction at 26.3k nuked the price. MMs have pulled liquidity until Barach and Bob have sorted the financing.
0 · Reply
NuclearMan
NuclearMan Jul. 30 at 10:32 AM
$CELU Well the 8K on minimum bid delinqency is ticked off. If Hariri and Barach remain quiet on the loan, the market will likely begin pricing in an unresolved senior secured debt risk. Being 'short sale restricted' today helps protect the stock from shorting of the bid. But doesn't protect it from pure selling. If market makers pull liquidity, the wider bid-askrspread could make the price volatile. Worth being prepared for that tbh.
1 · Reply
Coux
Coux Jul. 29 at 9:55 PM
$CELU new 8 K About the price being under 1$
1 · Reply
SkywalkerAR
SkywalkerAR Jul. 29 at 4:22 PM
$CELU bad news on the way?
0 · Reply
NuclearMan
NuclearMan Jul. 29 at 4:22 PM
$CELU Short sale restrictions just kicked in after that 10% drop. The Daily RSI is sub-40. If the company wanted an open goal for a decent PR, this is it.
0 · Reply
NuclearMan
NuclearMan Jul. 29 at 8:51 AM
$CELU This stock really has to declare some kind of resolution to the bridging loan today. I am guessing the dollar delinquency PR will be folded into that 8k. The 10Q did not file so we have to assume CELU submitted a plan to Nasdaq yesterday. Some clarification would be VERY welcome now.
2 · Reply
luckydog2
luckydog2 Jul. 27 at 1:35 PM
$CELU This is good news for Celularity/Biocellgraft. https://www.reddit.com/r/Biocellgraft/s/5c2dqRQ0ka
0 · Reply
Nosay
Nosay Jul. 27 at 12:38 PM
$CELU they haven’t even announced the IMUN thing but other companies they’re obviously working with are. Wonder why the silence. This is kind of big news. Where life bank was limited to a very small set of the population. People having new babies. This is open to all. Could be big if marketed well. Wish I was closer to New Jersey to go and see. And why is it referred to as Celularity campus? Something coming by Wednesday for sure. Barach loan is due.
0 · Reply
luckydog2
luckydog2 Jul. 26 at 1:46 PM
$CELU IMUN https://www.instagram.com/reel/Da206XPuZXA/?igsh=MWNrbjJ5czV5ZTQ4aw==
0 · Reply
NuclearMan
NuclearMan Jul. 23 at 7:53 AM
$CELU Filings due: 8K on minimum bid deliquency (probably filed Friday after hours). 10Q or submission of plan to Nasdaq (by 28 July). Extension of Barach loan OR paying off loan by 29 July. There may be other filings but these are ones we know have to happen. A critical four days now, tbh.
1 · Reply
dostephe
dostephe Jul. 22 at 8:37 PM
$CELU has anyone seen the latest filing? It looks like CELU is requesting to be delisted. Looking for more info now.
2 · Reply
luckydog2
luckydog2 Jul. 22 at 3:41 PM
$CELU “Turning medical waste into medical miracles” House passes Smith’s legislation to reauthorize and expand funding for umbilical cord blood stem cell research https://www.reddit.com/r/CelularityNews/s/3jtR6i7JV8
0 · Reply
NuclearMan
NuclearMan Jul. 22 at 11:48 AM
$CELU Expect the 8K notifying the company has traded 30 days under a dollar imminently. Deadline was Monday, CELU will receive from Nasdaq before Thursday and then has four days to file on EDGAR. Should be priced in but may create a retail wobble.
1 · Reply
Nosay
Nosay Jul. 20 at 1:56 PM
$CELU if both of those 50k buys decided to switch to market instead of limit this would be back to $1. Either way it’s nice to see them there!
1 · Reply
Nosay
Nosay Jul. 16 at 1:30 PM
$CELU I wonder if those celuw warrants expiring today will have any effect on anything. They were a LONG shot to ever get to a point of getting exercised. But starting tomorrow they’re off the books as potentially dilution.
1 · Reply
luckydog2
luckydog2 Jul. 15 at 6:18 PM
$CELU Milestone Moment For Fontaine Vitale Clinic It won't be long before it's up and running. https://www.reddit.com/r/CelularityNews/s/Z3WuFaARQV
0 · Reply
NuclearMan
NuclearMan Jul. 15 at 12:39 PM
$CELU By 28 July, Bob must file a 10Q or present Nasdaq with a plan to file a 10Q. If Bob fails to file a plan, the stock will be delisted. If Bob argues that he did not have the funding to file a 10Q, then his letter on 3 June is a "material misrepresentation" of the business and therefore fraud. The untapped ATM (see prev( and 1m/1month loan adds to the fishiness. I lnow I have been harping on about a 10Q but this is a genuine existential threat. I can't believe Hariri is a scammer, but the delay makes zero sense now. If he pulls a rabbit out of the hat, I will stand corrected obvs.
1 · Reply
NuclearMan
NuclearMan Jul. 15 at 12:11 PM
$CELU In early May 2026, this company was compliant on all fronts. At that point, given its cash situation, it could have exercised the existing ATM agreement it has in place to fund operations. It chose not to do so. It is now noncompliant and the ATM cannot be accessed. It retired all debt but has a cash runway of zero- needing a loan from Barach that is timed to default the day AFTER the 28 July deadline for filing a 10Q. This goes one of two ways, depending on if CELU has a rabbit to pull out of the hat. But if Bob lets the company default and bankrupt on 29 July, he has questions to answer.
0 · Reply
NuclearMan
NuclearMan Jul. 14 at 3:25 PM
$CELU FWIW I have been asking Gemini Pro to estimate the financials. It is a mixed bag. It says the Nexgel money has been allocated to paying off debt. It says future Nexgel money is going to pay off the Helena convertible note. It says the current $1M loan expires the day AFTER the Nasdaq deadline for filing a 10Q on 28 July. It says the trial costs are likely complete. But Barach holds first priority over the assets and IP. But adds that Bob *is* the IP and his common stock is in the toilet at a 1.60 average. It says the monies for paying CFOSquad should be there and the delay to the 10Q is likely an issue around the classification of remaining debt. BUT despite all that Gemini cannot explain why Bob took out a 1m loan, which deprioritises Hariri in the debt hierarchy.
0 · Reply
Nosay
Nosay Jul. 14 at 1:36 PM
$CELU another day and another nothing. Q2 is complete now. Only 31 days till those numbers are due and we’re still waiting for Q1. Things are obviously happening. 2 accounting jobs posted in their site. Both with salaries over 100k. Also that 30 day loan from Barach. Wtf was that? 15 days until maturity. But who risks 1 million for 4% interest over 1 month (only gaining 3300$!) if they don’t know something good is in the works. But also. Where did all the Nexgel deals money go? Why did they need 1 million. So many questions and absolute silence from the company.
1 · Reply